WuXi AppTec has filed a patent for a cell that can produce recombinant adenoviruses (AVs). The cell’s genome contains DNA molecules that can produce antisense RNAs against AAV cap and AAV rep mRNAs. The patent also covers the processes for producing these cells and using them to produce recombinant AVs. GlobalData’s report on WuXi AppTec gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on WuXi AppTec, AI-assisted drug screening was a key innovation area identified from patents. WuXi AppTec's grant share as of September 2023 was 31%. Grant share is based on the ratio of number of grants to total number of patents.
A patent for a process of producing recombinant adenoviral particles
A recently filed patent (Publication Number: US20230313228A1) describes a process for producing recombinant adenoviral (AV) particles. The process involves introducing a recombinant adenovirus genome into a plurality of cells. The recombinant adenovirus genome includes an AAV cap gene and/or an AAV rep gene. The cells also contain a first DNA molecule with a first promoter and a DNA molecule encoding an antisense RNA capable of binding to an AAV Cap mRNA, and/or a second DNA molecule with a second promoter and a DNA molecule encoding an antisense RNA capable of binding to an AAV Rep mRNA. These DNA molecules are stably integrated into the cell's genome. The cells are then cultured in a culture medium under conditions that result in the production of antisense RNAs capable of binding to AAV Cap mRNA and AAV Rep mRNA.
The patent claims also specify that the process can be performed using cells from an adenovirus production cell line or an adenovirus manufacturing cell line. The cells used in the process can be selected from a group of cell lines including HEK-293, HEK 293T, HEK-293E, HEK-293 FT, HEK-293S, HEK-293SG, HEK-293 FTM, HEK-293SGGD, HEK-293A MDCK, C127, A549, HeLa, CHO, mouse myeloma, PerC6, 911, and Vero cell lines, or derivatives thereof.
The patent also describes the characteristics of the antisense RNA molecules used in the process. These molecules can bind to the 5' or 3' UTR of an AAV Cap mRNA. The AAV Cap mRNA can encode VP1, VP2, or VP3 proteins. The antisense RNA molecules can also bind to the coding sequence of Rep78 or Rep68 mRNA. The degree of complementary nucleotide sequence identity between the antisense RNA and the corresponding region of the Cap mRNA or Rep mRNA can be at least 70%, 80%, 90%, 95%, or 100%. The length of the antisense RNA molecules can range from 18-27 nucleotides, 20-22 nucleotides, or 21 nucleotides. The antisense RNA molecules can be siRNA or miRNA.
The patent further describes the use of constitutive promoters, a repressible Major Late Promoter (MLP), and repressor elements to regulate or control transcription of adenoviral late genes in the recombinant adenovirus genome. The AAV cap gene in the recombinant adenovirus genome can be operably-associated with no promoter or a minimal promoter. The AAV Rep polypeptide expressed from the AAV rep gene can be at a low, baseline, or minimal level.
The patent also includes claims related to a cell that comprises the recombinant adenovirus genome, the first and second DNA molecules, and the stable integration of these DNA molecules into the cell's genome. Additionally, the patent describes a process for producing a recombinant cell by introducing the first and second DNA molecules and the recombinant adenovirus genome into a cell and culturing the cell under conditions that result in the stable integration of the DNA molecules into the cell's genome.
The process described in the patent can also include a step for purifying and/or isolating recombinant AV particles from the cells or the culture medium.
To know more about GlobalData’s detailed insights on WuXi AppTec, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
